WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:   || 2 |

«PACKAGE LEAFLET: INFORMATION FOR THE USER Cytarabine 100 mg/ml Injection Read all of this leaflet carefully before you start using this medicine. • ...»

-- [ Page 1 ] --

PACKAGE LEAFLET: INFORMATION FOR THE USER

Cytarabine 100 mg/ml Injection

Read all of this leaflet carefully before you start using this medicine.

• Keep this leaflet. You may need to read it again.

• If you have any further questions, ask your doctor.

• If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please

tell your doctor.

In this leaflet:

1. What Cytarabine Injection is and what it is used for

2. What you need to know before you use Cytarabine Injection

3. How to use Cytarabine Injection

4. Possible side effects

5. How to store Cytarabine Injection

6. Contents of the pack and other information

1. WHAT CYTARABINE INJECTION IS AND WHAT IT IS USED FOR

Cytarabine Injection is an anti-cancer medicine. Treatment with an anti-cancer medicine is sometimes called cancer chemotherapy.

Cytarabine Injection is used to treat some types of leukaemia (cancer affecting the blood) and lymphomas (cancer of the lymph glands). It may be used in combination with other anti-cancer medicines.

2. WHAT YOU NEED TO KNOW BEFORE YOU USE CYTARABINE INJECTION

Do not use Cytarabine Injection

• if you have shown signs of hypersensitivity (severe allergy) to cytarabine in the past, or any of the other ingredients of this medicine (listed in section 6)

• if your blood cell count (number of cells in your blood) is very low due to some cause other than cancer (unless your doctor decides the benefits of treatment outweigh the risks)

• if you have had severe effects on your brain (encephalopathy) after radiation treatment or treatment with another anticancer medicine such as methotrexate

• if you are pregnant (Unless your doctor considers the benefits to the mother outweigh the risks to the unborn child) Tell your doctor if you think any of the above applies to you before this medicine is used.

Take special care with Cytarabine Injection

• if your blood cell count is low

• if you have any problems with your liver including jaundice (causes yellowing of the skin)

• if you have recently received cancer medicine treatment or radiotherapy or if you are due to have radiotherapy (the side effects of radiotherapy can be made worse by cytarabine treatment)

• cytarabine strongly reduces blood cell production in the bone marrow and your blood cell numbers can continue to fall for up to a week after stopping treatment. Your doctor will test your blood regularly and examine your bone marrow if required

• if your bone marrow is still recovering from the effects of other medicines (your doctor will only consider treatment with cytarabine if absolutely necessary)

• serious and sometimes life-threatening side effects can occur in the central nervous system, the bowels, the lungs or the heart especially when treated with high doses of cytarabine

• the levels of uric acid (showing that the cancer cells are destroyed) in your blood (hyperuricaemia) may be high during treatment. Your doctor will tell you if you need to take any medicine to control this

• during treatment with cytarabine administration of certain vaccines is not advised. If required, consult your doctor

• during treatment with cytarabine, granulocyte transfusion should be avoided as severe breathing problems have been reported. Your doctor will determine if this treatment is required Tell your doctor if either of the above applies to you before this medicine is used. Your doctor will monitor your blood to check your blood cell count, your liver and kidney functions and to monitor for raised uric acid levels.

Special care will be taken if cytarabine is to be given to a child. Cytarabine should not be used in infants.

Taking/using other medicines Special care is needed if you are taking/using other medicines as some could interact with cytarabine.

The effectiveness of the following medicines may be reduced or increased by cytarabine:

• digoxin or beta-acetyldigoxin tablets (heart medicine)

• gentamicin (an antibiotic) • 5-fluorocytosine (a medicine used to treat fungal infections)

• other medicines which decrease the activity of the immune system Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

Pregnancy and breast-feeding Tell your doctor if you are pregnant, trying to become pregnant or breast-feeding. Your doctor will decide if you should receive this medicine.

Avoid becoming pregnant while you or your partner is being treated with cytarabine. As there is a risk of birth defects, women of childbearing potential or their partner should use appropriate contraception methods during and up to 6 months after treatment with cytarabine to prevent pregnancy.

You should stop breast-feeding before starting treatment with cytarabine because this medicine may be harmful to infants being breast-fed.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines Do not drive or use machines if you experience any side effect which may lessen your ability to do so.





3. HOW TO USE CYTARABINE INJECTION

This medicine may be given by injection (using a syringe) under the skin (subcutaneous) or into a vein (intravenous). It may also be given by infusion (drip) into a vein. If given as an infusion, Cytarabine Injection will be diluted first.

Cytarabine 100 mg/ml Injection must not be injected intrathecally (into the spine).

Dose Your doctor will work out the correct dose of cytarabine for you and how often it must be given.

The dose will depend on your medical condition, your size and how well your liver is working. Your doctor will tell how well your liver is working using blood tests.

You will have regular blood tests after your dose of cytarabine to check for side effects. These tests may be done more often if you are elderly, as you may be more likely to get side effects. Treatment may have to be stopped if your blood cell count drops too low.

If you are given too much or too little Cytarabine Injection This medicine will be given to you in a hospital, under the supervision of a doctor. It is unlikely that you will be given too much or too little, however, tell your doctor or nurse if you have any concerns.

4. POSSIBLE SIDE EFFECTS Like all medicines, Cytarabine Injection can cause side effects, although not everybody gets them.

If any of the following happen, tell your doctor or nursing staff immediately:

• sore mouth, particularly if you have a number of ulcers inside of the mouth

• severe allergic reaction - you may experience a sudden itchy rash (hives), swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing), and you may feel you are going to faint

• symptoms of an infection, e.g. fever, chills, aches or soreness when swallowing

• unexpected bleeding e.g. bleeding gums, blood in urine or vomit, unexpected bruises

• black tarry stools which may indicate bleeding in the digestive system

• severe pain in the chest and difficulty breathing (this maybe a symptom of pericarditis)

• severe pain in the abdomen (this may be a symptom of inflammation of the pancreas)

• loss of vision, loss of sense of touch, mental disturbance or loss of ability to move normally (this medicine may cause side effects to the brain and eyes which are usually reversible but may be very serious) These are serious side effects. You may need urgent medical attention.

If you experience any of the following tell your doctor as soon as possible:

The side effects of cytarabine are dependent on the dose. The digestive tract is most commonly affected, but also the blood.

Common side effects which may affect up to 1 person in 10 are listed below:

• decrease in cells responsible for providing immunity, carrying oxygen around the body and for normal blood clotting shown as a reduction in the amount of red and white cells and platelets in the blood or abnormal red blood cells, anaemia, shortness of breath, unexpected bleeding e.g. bleeding gums, blood in urine or vomit, unexpected bruises

• loss of appetite

• high levels of uric acid in your blood due to the breakdown of cancer cells during treatment with cytarabine (your doctor will monitor for this)

• reduced consciousness, speaking difficulties, abnormal eye movements (nystagmus)

• reversible effects on the eyes such as sore eyes with bleeding (haemorrhagic conjunctivitis), vision disturbance, sensitivity to light (photophobia), watery or burning eyes and inflammation of the surface of the eye (cornea) (keratitis)

• feeling or being sick, diarrhoea, sores or ulcers in the mouth or anus (back passage), mild pain in the abdomen

• reversible effects on the liver such as increased enzyme levels

• reversible effects to the skin such as reddening (erythema), blistering, rash, hives, blood vessel inflammation (vasculitis)

• hair loss

• impaired / disturbed kidney function, problems passing urine

• fever

• blood clots causing inflammation at the site of injection

Uncommon side effects which may affect up to 1 person in 100 are listed below:

• whole body infection (sepsis) seen as a fever, vomiting, confusion, dizziness, chills

• lung infection

• headache

• numbness or weakness of the arms and legs, paralysis of the legs and lower body when cytarabine is given into the space surrounding the spinal cord (intrathecal)

• inflammation of the sac that surrounds the heart

• shortness of breath

• sore throat

• inflammation of the food pipe (oesophagus), ulcers in the food pipe

• bowel cysts, severe bowel inflammation, serious infection of the membrane that lines the abdomen (peritonitis)

• brown/black spots on the skin (lentigo), ulceration of the skin, itching

• painful redness and blistering on the hands and the soles of the feet

• joint and muscle pain

• inflammation at the site of injection

Very rare side effects which may affect up to 1 person in 10,000 are listed below:

• irregular heart beat (arrhythmia)

• redness and itchy bumps on hands or legs, associated with inflammation of the sweat glands

Not known (cannot be estimated from available data) side effects are listed below:

• low counts of pre-stages of red cells in the blood (reticulocytopenia)

• dizziness, inflammation of a nerve or part of the nervous system, damage to nerve tissues and pain

• sore or itchy eyes

• black tarry stools which may indicate bleeding in the digestive system

• impaired liver function

• yellowing of the skin or yellowing of the whites of the eyes (jaundice)

• skin rash, pigmented spots on the skin (freckles), skin bleeding

• kidneys may not work properly

• lack of periods and low sperm count (Amenorrhoea and azoospermia)

• chest pain

• irritation or infection at the site of injection

• bleeding of the lining of the mouth The side effects on the digestive tract are less if cytarabine is given by infusion rather than by bolus injection. Your doctor may prescribe local steroids (anti-inflammatory medicines) to reduce effects on the eyes such as sore eyes with bleeding (haemorrhagic conjunctivitis).

Cytarabine may lead to changes in your blood cells. Your doctor will take blood samples to monitor for these and also to check how well your liver and kidneys are working.

Sometimes the following side effects can occur together, usually 6-12 hours after receiving cytarabine:

• feeling generally unwell with a high temperature

• pain in bone, muscle and occasionally the chest

• rash

• sore eyes This is known as ‘cytarabine syndrome’ and it can be treated. If you experience these side effects please tell your doctor or nurse as soon as possible.

Side effects after high dose Cytarabine treatment:

Severe and at times fatal side effects on the blood, eyes, lungs, nervous system, liver, digestive or genital system have been reported after using experimental dose schedules. The side effects have included severe bone marrow suppression, reversible effects on the cornea (surface of the eye), effects on the brain (usually reversible), drowsiness and convulsion, ulcers in the digestive system which may lead to infection of your abdominal lining (peritonitis), inflammation of the pancreas, liver abscess or enlargement, blood clots in the vein in the liver, blood infection, fluid in the lungs, absence of menstrual periods in women or complete lack of sperm in the ejaculate in men, heart muscle disease or abnormal muscle breakdown, which may lead to kidney problems (rhabdomyolysis).

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.

Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

You can also report side effects directly via:

United Kingdom Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard By reporting side effects you can help provide more information on the safety of this medicine.

5. HOW TO STORE CYTARABINE INJECTION

Keep out of the reach and sight of children Expiry This medicine must not be used after the expiry date which is stated on the vial and carton after 'EXP'.

Where only a month and year is stated, the expiry date refers to the last day of that month.

Storage The vial should be kept in the outer carton, in order to protect from light, and stored at, or below, 25°C.

Do not refrigerate or freeze.

6. CONTENTS OF THE PACK AND OTHER INFORMATION



Pages:   || 2 |


Similar works:

«Package leaflet: Information for the user Bisoprolol HCT STADA 2.5 mg/6.25 mg, 5 mg/12.5 mg and 10 mg/25 mg film-coated tablets Bisoprolol/ Hydrochlorothiazide Read all of this leaflet carefully before you start taking this medicine becaus it contains important information for you.  Keep this leaflet. You may need to read it again.  If you have any further questions, ask your doctor or pharmacist.  This medicine has been prescribed for you only. Do not pass it on to others. It may harm...»

«National Occupational Health and Safety Commission DISEASES ACQUIRED FROM ANIMALS December 1989 Australian Government Publishing Service Canberra WAP 89/028 GS 006-1989 © Commonwealth of Australia 1989 ISBN 0 644 09192 4 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without written permission from the Director Publishing and Marketing, AGPS. Inquiries should be directed to the Mana ger, AGPS Press, Australian...»

«NAHEMS GUIDELINES: PERSONAL PROTECTIVE EQUIPMENT (PPE) FAD PReP Foreign Animal Disease Preparedness & Response Plan NAHEMS National Animal Health Emergency Management System United States Department of Agriculture • Animal and Plant Health Inspection Service • Veterinary Services APRIL 2011 The Foreign Animal Disease Preparedness and Response Plan (FAD PReP)/National Animal Health Emergency Management System (NAHEMS) Guidelines provide a framework for use in dealing with an animal health...»

«Blood and Marrow Stem Cell Transplantation Revised 2013 A Message from Louis J. DeGennaro, PhD President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) is committed to bringing you the most up-to-date blood cancer information. We know how important it is for you to have an accurate understanding of your diagnosis, treatment and support options. With this knowledge, you can work with members of your oncology team to move forward with the hope of remission and...»

«Corporate Fact Sheet ResMed changes lives by developing, manufacturing and distributing market-leading medical equipment for treating, diagnosing and managing sleep-disordered breathing, COPD, and other chronic diseases. Throughout our 25 years of research and innovation, we have continued to pioneer solutions that improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated...»

«PACKAGE LEAFLET 1 Package leaflet: Information for the user /./ 70 mg tablets Alendronic acid Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.Keep this leaflet. You may need to read it again.If you have any further questions, ask your doctor or pharmacist.This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side...»

«The Kennel Club Glossary of Canine Terms Introduction The Breed Standard is the “Blueprint” of the ideal specimen in each breed approved by a governing body e.g. The Kennel Club, the Federation Cynologique Internationale (FCI) and the American Kennel Club. Following agreement at the 1981 World Congress of Kennel Clubs, The Kennel Club changed all its Breed Standards into a standard format to enable easy comparison. The Kennel Club writes and revises Breed Standards taking account of the...»

«© World Health Organization WHO Technical Report Series No 941, 2007 Annex 5 WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines This document provides guidance to national regulatory authorities and vaccine manufacturers on the safe production and quality control of human influenza vaccines produced in response to a threatened pandemic. The document details international biosafety expectations for both pilot-scale and...»

«November 2010 The Impact of the H1N1 Pandemic on Canadian Hospitals Introduction Pandemic planning is a critical function for any health system. These plans aim to limit serious illness and death from a pandemic; they also ensure that essential health services are maintained and disruption of other health services is minimized. Achieving the goals of a pandemic plan requires the coordination of many agencies and institutions, from public health to acute care hospitals, and requires the...»

«Testing New Health Warning Messages for Cigarette Packages: A Summary of Three Phases of Focus Group Research Final Report Prepared for: Health Canada Prepared by: Environics Research Group Limited May, 2000 PN4591 TABLE OF CONTENTS 1.0 INTRODUCTION 2.0 INTRODUCTORY TOPICS 2.1 Awareness of Health Risks of Smoking 2.2 Awareness and Recall of Current Warning Messages 2.3 Support for and Perceived Impact of Warning Messages 3.0 NEW WARNING MESSAGES 3.1 Overall Response to New Warning Messages 3.2...»

«Somersault Software Fault-Tolerance Paul Murray, Roger Fleming, Paul Harry, Paul Vickers Internet Communication Services Department HP Laboratories Bristol HPL-98-06 January, 1998 software The ambition of fault-tolerant systems is to provide fault-tolerance, application transparent fault-tolerance at the same process replication performance as a non-fault-tolerant system. Somersault is a failure masking, library for developing distributed fault-tolerant software continuous systems that comes...»

«Real patients coming to real harm Ophthalmology services in Wales Dr Tammy Boyce 1 Acknowledgements I would like to express my gratitude to the clinical staff from health boards in Wales who were willing to share their experiences and insights into some of the capacity issues in the hospital eye service and the impact that this has on patients’ sight. Our thanks also go to Dr Tammy Boyce, the Royal College of Ophthalmologists, Alex McMillan, Sian Biddyr, Elin Wyn and Andy Williams at RNIB...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.